HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form

被引:21
作者
Sulebhavikar, A. V. [1 ]
Pawar, U. D. [2 ,3 ]
Mangoankar, K. V. [2 ,3 ]
Prabhu-Navelkar, N. D. [2 ,3 ]
机构
[1] KJ Somaiya Senior Coll Sci & Commerce, Dept Chem, Bombay 400077, Maharashtra, India
[2] Mithibai Coll Arts, Chaun Inst Sci, Dept Chem, Bombay 400056, Maharashtra, India
[3] Amrutben Jivanlal Coll Commerce & Econ, Bombay 400056, Maharashtra, India
关键词
Lopinavir; Ritonavir; HPTLC; Pharmaceutical formulation;
D O I
10.1155/2008/539849
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A rapid and simple high performance thin layer chromatography (HPTLC) method with densitometry at lambda=263 nm was developed and validated for simultaneous determination of lopinavir and ritonavir from pharmaceutical preparation. Separation was performed on aluminum-backed silica gel 60F(254) HPTLC plates as stationary phase and using a mobile phase comprising of toluene, ethyl acetate, methanol and glacial acetic acid, in the volume ratio of 7.0:2.0:0.5:0.5 (v/v) respectively. After development, plates were observed under UV light. The detector response was linear in the range of 6.67 to 20.00 mu g/spot and 1.67 to 5.00 mu g/spot for lopinavir and ritonavir respectively. The validated lowest limit of detection was 21.00 ng/spot and 5.10 ng/spot whereas lowest limit of quantification was 7.00 ng/spot and 21.00 ng/spot for lopinavir and ritonavir respectively. The percentage assay of lopinavir and ritonavir was found between 98.23 to 102.28% and 98.03 to 103.50% respectively. The described method has the advantage of being rapid and easy. Hence it can be applied for routine quality control analysis of lopinavir and ritonavir from pharmaceutical preparation and stability studies.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 28 条
[1]   Efavirenz [J].
Adkins, JC ;
Noble, S .
DRUGS, 1998, 56 (06) :1055-1064
[2]  
[Anonymous], 1996, HIGH PERFORMANCE THI
[3]  
[Anonymous], INT C HARM TRIP GUID
[4]   Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography [J].
Bouley, M ;
Briere, C ;
Padoin, C ;
Petitjean, O ;
Tod, M .
THERAPEUTIC DRUG MONITORING, 2001, 23 (01) :56-60
[5]  
Budavari S, 1996, MERCK INDEX, V8402, P1418
[6]   Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS [J].
Chi, JD ;
Jayewardene, AL ;
Stone, JA ;
Motoya, T ;
Aweeka, FT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (03) :675-684
[7]   High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications [J].
Choi, Sun Ok ;
Rezk, Naser L. ;
Kashuba, Angela D. M. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 43 (04) :1562-1567
[8]  
Corett A H, 2002, ANN PHARMACOTHER, V36, P1193
[9]   High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction [J].
Dailly, E ;
Thomas, L ;
Kergueris, MF ;
Jolliet, P ;
Bourin, M .
JOURNAL OF CHROMATOGRAPHY B, 2001, 758 (02) :129-135
[10]   Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].
Dickinson, L ;
Robinson, L ;
Tjia, J ;
Khoo, S ;
Back, D .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 829 (1-2) :82-90